In a setting of T1D and late-stage (insulin-deficient) T2D, hypoglycemia is the most common complication of intensive glucose-lowering therapy using insulin analogues and/or secretagogues (i.e., sulfonylureas and glinides; T2D only) (Cryer, 2002). The gene discussed is INS; the disease is Hypoglycemia.